A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Multiple Myeloma
DRUG: Alnuctamab|DRUG: Pomalidomide|DRUG: Daratumumab|DRUG: Elotuzumab|DRUG: Carfilzomib|DRUG: Dexamethasone
Progression-free Survival (PFS), Up to 5 years
Overall Survival (OS), Up to 5 years|Overall response (OR), Up to 5 years|Complete response (CR) or better, Up to 5 years|Very good partial response (VGPR) or better, Up to 5 years|Time to response (TTR), Up to 5 years|Duration of response (DOR), Up to 5 years|Time to progression (TTP), Up to 5 years|Time to next treatment (TTNT), Up to 5 years|Progression-free survival 2 (PFS2), Up to 5 years|Restricted mean DOR (RMDOR), Up to 5 years|Minimal residual disease (MRD) negativity rate, Up to 5 years|Incidence of adverse events (AEs), Up to 5 years|Incidence of serious adverse events (SAEs), Up to 5 years|Change from baseline in subscale scores of European organization for research and treatment of cancer - quality of life core 30 (EORTC QLQ-C30), Up to 5 years|Change from baseline in subscale scores of European quality of life multiple myeloma module (EORTC QLQ-MY20), Up to 5 years
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).